57 results about "Serum neutralization" patented technology

The invention discloses a recombinant varicella zoster virus vaccine, which comprises an amino acid sequence of a recombinant glycoprotein gE extracellular region of a live attenuated VZV strain (OKA strain) gene and a fusion protein formed by a human immunoglobulin Fc segment, and further comprises preparation and an application of the fusion protein, and a corresponding recombinant gene, an eukaryotic expression vector and the like. The fusion protein provided by the invention has good immunogenicity, and can induce generation of a high-level serum neutralizing antibody.

The invention discloses a preparation method and a special culture medium of veterinary D-type clostridium perfringen toxin. The culture medium per 100ml comprises the following components: 1-1.5g soy peptone, 1-1.5g casein peptone, 0.5-0.75g yeast extract, 0.5-0.75g Na2HPO4.12H2O, 1-1.5g dextrin and the balance of water, wherein a pH (potential of hydrogen) value of the culture medium is 8.0-8.5. The preparation method of the D-type clostridium perfringen toxin comprises the steps of inoculating a D-type clostridium perfringen production strain into the culture medium, collecting a culture material, performing centrifugation, and then filtering a supernate. With the adoption of the method, the maximum toxicity can be improved to be 45 times a seedling standard in Regulations on National Veterinary Biological Products, and an output-input ratio can be increased to be 30-225 times that of the original traditional technology. In addition, corresponding serum neutralization titer of a toxoid vaccine prepared by the D-type clostridium perfringen toxin on a rabbit and a sheep is also improved to be 8.3 and 13.3 times a regulation standard respectively.

The invention discloses a type B Clostridium perfringens exotoxin, a preparation method thereof, a toxin-producing medium and an application thereof. Wherein every 1000ml described toxin-producing medium is made of the raw materials of following weight ratio: peptone 15-25g, yeast extract powder 3-5g, NaCl 3-4g, NaCl 2 HPO 4 12H 2 O 5‑10g, dextrin 5‑10g or crude dextrin 5‑10g, and the rest is water for injection. The virulence of the type B Clostridium perfringens toxin prepared by the method of the invention can reach up to 1 mouse MLD≤0.0006mL, which is 3.3 times higher than the seedling production standard. Moreover, the neutralization titer of the corresponding serum neutralization titers of rabbits and sheep in the triple inactivated vaccine of sheep rapid epidemic disease and sudden attack (or lamb dysentery) enterotoxemia also reaches or exceeds the standard of relevant regulations.

The invention belongs to the field of medical biotechnology and discloses a test strip for joint screening of early esophageal cancer. The test strip includes a binding pad and a chromatography pad, and the binding pad is coated with a mouse anti-human IgG monoclonal antibody and a rabbit IgG monoclonal antibody. Antibodies, mouse anti-human IgG monoclonal antibody and rabbit IgG monoclonal antibody all have detectable markers; there are three detection lines and one quality control line on the chromatography pad, and the detection antigens coated on the three detection lines are KPNA6 protein, PDE1A protein, CASK protein; the quality control belt is coated with goat anti-rabbit IgG. The test strip of the present invention combines KPNA6 protein, PDE1A protein, and CASK protein, three tumor-associated antigens, as markers for early esophageal cancer screening, and is used to detect the expression levels of autoantibodies of KPNA6, PDE1A, and CASK in serum, which can effectively Detection of esophageal cancer, especially early esophageal cancer, has greatly improved the detection rate of early esophageal cancer.